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1. Introduction 
Since old times plants have been a resource used by human beings an important sources of 
biologically active products. Recently, efforts have been made in order to identify new 
antiulcerogenic drugs from natural sources, having as the main target the Helicobacter pylori, 
a bacterium considered as the most important etiological agent of the human peptic ulcer. It 
has been shown to be a rich source of bioactive substances, having antifungal, 
gastroprotective, analgesic, anti-HIV, antibacterial, antitumoral properties and inhibitor of 
gastric H+,K+-ATPase and angeotensin-converting enzyme. This chapter aims to 
demonstrate methods anti-Helicobacter pylori in vitro and in vivo for screening of plant 
extracts. 
Helicobacter pylori was identified in 1982 by Marshall and Warren (1984) and quickly 
became the subject of countless microbiological, histological, epidemiological, 
immunological, ecological and clinical studies (Vaz, 2005). This organism has its 
nomenclature revised, starting with Campylobacter pyloridis, and a correction of the name 
was originally Greek to Latin, Campylobacter pylori (Marshall and Goodwin, 1987) and 
organisms like Campylobacter. Taxonomic studies have led to reclassification, resulting in 
the name Helicobacter pylori (Goodwin and Armstrong, 1990). 
H. pylori is a bacillus, Gram negative, microaerobic, spiral and curved (Dunn et al. 1997). It 
has two to six flagella that provide motility to it to resist the rhythmic contractions of 
stomach and penetrate the gastric mucosa. It has 2.4 to 4.0 mm in length and 0.5 to 1.0 mm 
in width (Brown, 2000). 
The identification and isolation of Helicobacter pylori allowed for a considerable development 
of knowledge about peptic ulcer (Marshall and Warren, 1984). This pathogen is considered 
the main etiological agent of human peptic ulcer, with a worldwide prevalence rate of about 
40% in developed countries and over 80% in developing countries (Shi et al., 2008).  
H. pylori produces a number of virulence factors that may have different associations with 
the disease. The establishment of chronic infection may be influenced by host genetic factors 
as well as the blood group ABO and Lewis-blood group antigen and differences in 
susceptibility to particular strains of H. pylori (Brown, 2000). 
To establish and maintain the infection, H. pylori expresses a variety of different types of 
maintenance factors that allow bacteria to colonize and remain within the host and virulence 
factors, which contributes to the pathogenic effects of bacteria, with emphasis on gastric 
inflammation, mucosal barrier disruption gastric and changes in gastric physiology (Dunn 
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et al. , 1997). H. pylori is a genetically highly diverse bacterium, featuring several genotypes 
which have been associated with virulence factors and risk of gastric disease and other 
outcomes of infection. Among these, the vacA gene, which encodes a cytotoxin of 
vacuolization, is present in all types of H. pylori. This gene is also strongly associated with 
high levels of inflammation and epithelial damage in the gastric mucosa, caused by cagA 
gene is a marker for the presence of PAI pathogenicity (cag pathogenicity island) (Ladeira et 
al., 2003). 
In previous studies, infection with different types of Helicobacter, as H. mustela, H. felis, H. 
heilmanii, and H. pylori in mice, cats, pigs, monkeys and gerbils have been described 
suggesting its relevance to human infection, but these animal models do not mimic the 
infection of H. pylori in humans because of the lack of virulence factors of infecting 
organisms, such as vacA and cagA encoded cytotoxins, required for the mucosal damage, 
inflammation and ulcer formation (Konturek et al., 2000). Moreover, some of these animals 
are large and unwieldy, there is a need to test commonly used in animal models such as 
mice, which could be used to study various aspects of infection by H. pylori, ulcer healing 
and therapy of infection (Ross et al., 1992). 
Results in experimental studies in animal models using rodents, concluded that H. pylori 
alone causes little or no effect on the gastric mucosa of intact rats. However, this organism 
can cause persistence of pre-existing ulcers and chronic active inflammation. Presence of 
predisposing factors leading to disruption of the integrity of the gastric mucosa may be 
necessary for the H. pylori enhancement inflammation and tissue damage to the stomach of 
these animals (Konturek et al 2000). Whereas peptic ulcer is generally a disease which 
results from the circumscriptive loss of tissue in regions of the digestive tract that may come 
into contact with the stomach’s chloride peptic secretion (Coelho, 2003). In general, it is 
caused by an imbalance between aggressive and defensive factors of the gastric mucosa 
(Rao et al., 2000). It seems that the Helicobacter pylori takes advantage of this situation to 
colonize and settle in the gastric mucosa. 
2. Experimental protocols 
2.1 Animals 
Male Wistar albino rats (160-210 g) and male Swiss-Webster mice (25-30 g), can be used. The 
animals should be kept in propylene cages at 26±2ºC under 12h light-dark cycle, with free 
access to water and restricted access to food, 2 hours/day (9-10a.m. and 6-7p.m.).  
2.2 Microorganism 
The strain of Helicobacter pylori ATCC 43504 (vacA and cagA positives) can be used to 
express the factors that determine their virulence. Stock cultures can be maintained in 
Mueller-Hinton broth at -20ºC. 
2.3 Botanical material 
Plants should be carefully collected and treated to prevent fungal contamination. The plants 
should be deposited, registered and taxonomically verified. 
2.4 Extract preparation and phytochemical analysis 
Plants should be cleaned, dried at room temperature and shredded in an electric mill with a 
sieve with a mesh size of 40µm, until powder be obtained. The dried powder should be 
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successively macerated (1:5, w/v), with hexane, dichloromethane, ethyl acetate, methanol 
and water-ethanol 75%, for 7 days each. Every extract should be separated by filtration and 
concentrated under reduced pressure at, approximately, 40ºC, with the residual solvent 
being eliminated in an incubator at 40ºC. To prepare the dichloromethanic fraction (Fig. 1), 
the crude dichloromethanic extract should be submitted to silica filtration using 
dichloromethane. The preliminary phytochemical analyses of the hydroethanolic extract and 
the dichloromethanic fraction may follow the methodology described by Matos (1998). 
 
 
Fig. 1. Scheme of preparation of extracts and fractions 
2.5 In-vitro assays 
2.5.1 Disk diffusion 
For the disk diffusion assay, serial dilutions of the hexanic, ethyl acetate, dichloromethanic, 
methanolic and hydroethanolic extracts from plants, should be prepared, in order to obtain 
the following doses: 0.0625; 0.125; 0.25; 0.5 and 1 mg/disk. The sterile disks utilized (6 mm - 
CECON®) should be imbibed in 25µL of each dose of extract and fraction. The extract- or 
fraction-imbibed disks should be deposited on the surface of the plate inoculated with H. 
pylori, in a suspension of 6x108 CFU/mL (McFarland turbidity standard 2), using 
clarithromycin (15µg - CECON®) as the standard drug, incubated at 37°C under 
microaerophilic conditions in an atmosphere of 5 to 15% O2 and 5 to 10% CO2 for 3-5 days. 
After this period, the growth inhibition halos should be quantified with a digital 
pachymeter. The diameters of inhibitory zones should be measured in duplicate and mean 
values ≥10 mm are considered active (Fig. 2). 
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Fig. 2. Photograph (A) and scheme (B) of a disk diffusion 
2.5.2 Broth microdilution 
The broth microdilution assay allows the determination of the Minimum Inhibitory 
Concentration (MIC). To each well in the microplate should be added 100µL of Mueller-
Hinton broth, supplemented with 10% foetal calf serum inoculated with 6x108 H. pylori 
(McFarland turbidity standard 2), 100µL of the hexanic, ethyl acetate, dichloromethanic, 
methanolic and hydroethanolic extracts from plants, should be also added to reach the final 
concentrations of 0.0625; 0.125; 0.25; 0.5 and 1 mg/mL. Clarithromycin (5 mg/mL) is used as 
the standard drug for growth inhibition. Next, the microplate (Fig. 3), should be incubated 
at 37°C under microaerophilia in an atmosphere of 5 to 15% O2 and 5 to 10% CO2, for 3-5 
days. After incubation, the plates should be visually examined and each well should be 
replicated in blood agar (Mueller-Hinton agar with 5% sheep blood), to determine whether 
growth had occurred, with the MIC defined as the lowest concentration to cause complete 
bacterial growth inhibition (bactericidal activity). 
 
 
Fig. 3. Photograph of a microdilution plate 
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2.6 In-vivo assays 
2.6.1 Acute toxicity evaluation 
The acute toxicity evaluation of each extract of plant should be performed in mice (n = 4). 
The animals should be treated orally (p.o.) with extract at 250, 500, 1000, 3000 and 5000 
mg/kg doses. A control animal should be used for each dose, having received the vehicle 
(distilled water, 10 mL/kg). After the administration of the extract or vehicle, the animals 
should be observed individually in appropriate cages (open field) at 0, 15 and 30 minutes; 1, 
2, 4 and 8 hours and, once every day, for 14 days. The results for the general behavioural 
observations should be recorded in a table adapted from Malone (1977).  
2.6.2 Ulcer induction and colonization by H. pylori  
Rats should be ulcerated by acetic acid according to method described by Takagi et al. 
(1969), with modifications. After ulcer induction, the animals should be kept in propylene 
cages, with daily access to commercial food restricted to the time periods of 9-10 a.m. and 5-
6 p.m., allowing for adequate fasting for administration of H. pylori, and of extract at 50, 100 
and 200mg/kg doses of preparations, as well as of the standard drugs (amoxicillin 50mg/kg 
+ clarithromycin 25mg/kg + omeprazole 20mg/kg). 
According to the method described by Konturek et al. (1999), with modifications, 24h after 
ulcer induction by acetic acid, the animals should be inoculated intragastrically with 1 mL of 
H. pylori ATCC 43504 (9x108) suspended in Mueller-Hinton broth, by using a cannula 
appropriate for orogastric gavage. For the animals in the control, Sham and acetic acid-
induced ulcer groups without H. pylori infection, only Mueller-Hinton broth should be 
orally administered. The orogastric inoculation of H. pylori should be maintained twice a 
day for 7 days, whereas the administration of extracts from plants and of the standard 
drugs, twice a day, for 14 consecutive days, starting from the third day after ulcer induction 
by acetic acid. After treatment, the animals should be sacrificed by cervical dislocation; 
blood can be collected from the inferior vena cava. The stomachs should be removed for 
evaluation of gastric lesions, the ulcerated area (mm2) should be measured and the healing 
rate (%) and then determined according to method described by Takagi et al. (1969). 
Prostaglandin E2 (PGE2) levels should be measured from gastric mucosal scrapings and a 
fragment from each stomach can be used for the histopathological exam and for the urease 
determination. 
2.6.3 Determination of PGE2 concentration 
The concentration of PGE2 in scrapings of gastric mucosa should be quantified by ELISA 
using a commercial kit (Parameter®, R&D Systems). The mucosal scrapings (100 mg) 
should be homogenized with 1 mL phosphate buffer and centrifuged at 3,000 RPM at 4ºC 
for 10 min. The PGE2 levels should be determined according to the manufacturer’s 
instructions.  
It has been demonstrated that PGE2, derived from COX-1 and COX-2, is involved in the 
regulation of gastric mucosa inflammation and also contributes to maintaining its integrity 
during infection by H. pylori through several mechanisms, including augmentation of the 
gastric mucosal flow, synthesis of mucus and bicarbonate, inhibition of gastric motility, and 
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2.6.4 Urease production determination 
With the aid of tweezers, a fragment of gastric tissue should be inserted in the centre of a 
minitube containing urease gel (NEWPROV®). Inoculation times should be recorded, the 
minitubes should be kept at room temperature and the change in colour should be 
evaluated after 1 hour, and whenever it is negative, a final reading should be taken after 24 
hours. A urease test should be considered positive if an alkaline reaction has developed (red 
or dark pink colour), and negative when there are no changes in the medium’s colour 
(yellow or light orange). 
Urease, an enzyme produced by H. pylori, acts by promoting the hydrolysis of urea, a 
substrate that is present in gastric juice under physiological conditions, leading to the 
production of ammonium, that behaves as a receptor for H+ ions and generates a neutral pH 
inside the bacteria, thus contributing to the survival of these organisms in the highly acidic 
environment of the stomach (Ladeira et al., 2003). The rapid urease test is considered one of 
the most useful and cheapest tests among the invasive assays, with a 100% sensitivity and 
89.5% specificity (Ogata et al., 2002), although false positive results may occur given the 
other bacterial species that might be isolated from the oral and/or gastric cavities (Proteus 
mirabilis, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter cloacae and Staphylococcus 
aureus) and that also produce urease (Osaki et al., 2008).  
2.6.5 Determination of cytokines IL-1β, TNF-α, IL-10 and VEGF 
Total blood should be collected from the inferior vena cava, in tubes containing 5% EDTA, 
centrifuged at 3000 RPM for 10 min., and the plasma should be separated and frozen at -
20ºC until the assay. For measuring plasma levels of IL-1ǃ, TNF-ǂ, IL-10 and VEGF, a plex 
kit for rat cytokines and chemokines (RCYTO-80K) should be used according to the 
manufacturer’s instructions, and the fluorescence should be determined through a Luminex 
® device. 
The literature refers to IL-1ǃ as being the most potent among the known gastroproctective 
agents (Kondo et al., 1994; El-Omar, 2004). TNF-ǂ also inhibits gastric secretion, although to 
a lesser extent than IL-1ǃ and is found, together with IL-10, elevated in patients with chronic 
gastritis associated with H. pylori infection (El-Omar, 2004). VEGF has been mentioned as a 
cicatrisation-promoting factor in gastric ulcer (Okabe and Amagase, 2005). 
2.6.6 Histopathological analysis 
After their removal, half of each stomach should be fixated in 10% buffered formalin and 
embedded in paraffin. From each block, two 5µm sections should be made, one being 
stained by hematoxilin and eosin (HE) and the other by a modified Giemsa stain for H. 
pylori detection.  
All tissues should be examined by a pathologist, according to criteria established by Dixon 
et al. (1996), and the following parameters should be analyzed: 
 Inflammation - presence of lymphocytes and plasmocytes in the lamina propria; 
 Activity – characterized by the presence of neutrophils inside the superficial and 
glandular epithelial layers; 
 Regeneration - characterized by a proliferative response to epithelial lesion, in which 
epithelial cells presenting larger hyper-stained / excessively stained nuclei, with an 
increase in the nucleus-cytoplasm ratio, and observation of occasional mitotic figures;  
 Atrophy – reduction of glandular structures; 
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 Metaplasia - presence of caliciform cells with an intestinal morphology. 
2.6.7 Statistical analyses 
Results for the parametric tests should be expressed as mean ± standard error of the mean 
(S.E.M.). Statistical significance should be determined by one-way analysis of variance 
(ANOVA), followed by Tukey-Kramer or Dunnett’s post-test. For frequency comparisons, 
Fisher’s exact test should be used, and p values <0.05 should be considered significant. 
3. Some considerations 
Gastrointestinal diseases are one of the most important causes of the previously high 
morbidity rates in non-industrialized countries, which have been lowered, in part, by the 
many drugs employed for treatment of peptic ulcers. However, such drugs may have 
several side effects, on top of their high financial cost for underprivileged populations 
(Borrelli and Izzo, 2000). Therefore, the use of medicinal plants and the development of 
phytotherapies, at a low cost, would represent an alternative for treatment of 
gastrointestinal problems for a large population segment that does not have access to 
medication (Sartori 1997). In Brazil, numerous plant extracts are used in conventional 
medicine to treat many digestive disorders (Falcão et al., 2008). 
With respect to the in vitro assays, it is important to emphasize that the disk diffusion 
method is recommended for studying polar substances, given that it allows the evaluation 
of different compounds against a microorganism and, therefore, establishes its antibacterial 
spectrum. For non-polar extracts the employment of diffusion techniques seems inadequate, 
since they do not readily diffuse in agar. In the broth microdilution method, the compound 
to be tested is mixed into the proper liquid medium that had been previously inoculated 
with the microorganism, allowing determination as to whether the compound is 
bacteriostatic (minimum bacteriostatic concentration) or bactericidal (minimum bactericidal 
concentration – MBC). It presents a higher sensitivity to drugs than the disk diffusion 
method because it permits direct contact between the drug and the microorganism and is, 
therefore, appropriate for assays assessing either polar or nonpolar substances (Rios and 
Recio, 2005).  
With respect to the in vivo assays, the establishment of a persistent infection by H. pylori in 
laboratory animals that completely reproduces the basic characteristics of human infections 
(an intense active chronic gastritis, either antral or diffuse), their complications (mucosa 
atrophy and intestinal metaplasia) and their associated pathologies (peptic ulcer, gastric 
adenocarcinoma and lymphoma) is not easy to accomplish. Chronic ulcer by acetic acid 
injection into the gastric subserosa area, differently from acute ulcers, penetrates the muscle 
layer of the glandular area and, occasionally, relapses after wound healing, and is highly 
similar to the human gastric ulcer in light of its pathological characteristics and healing 
process (Okabe and Pfeiffer, 1972).  
Previous results indicate that Wistar rats with pre-existing gastric ulcers, experimentally 
produced by acetic acid injection, developed active ulcers when exposed to H. pylori, similar 
to the results of Konturek et al. (1999), which were obtained with a different species (Souza 
et al, 2009). 
In order to evaluate the in vivo anti-H. pylori activity and to verify the presence of this 
bacteria in the gastric mucosa of ulcerated infected rats, the urease test and histopathological 
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analysis should be carried out and monitored by the degree of cicatrisation of the gastric 
lesion. 
The histopathological exam is considered one of the most specific tests for diagnosing H. 
pylori infections, presenting 98% sensitivity and 97% specificity (Lin et al., 1996; Ogata et al., 
2002). The histopathological findings confirm the results found in the urease test, in which 
treatment of animals, ulcerated and inoculated with H. pylori. Moreover, parameters such as 
inflammation, ulcer persistency and neutrophilic activity, which are characteristics of H. 
pylori infection. 
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